- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT01466855
A Study of Intra-Ophthalmic Artery Topotecan Infusion for the Treatment of Retinoblastoma (IARB1)
A Pilot Study of Intra-Ophthalmic Artery Topotecan Infusion for the Treatment of Retinoblastoma
This study will test if giving topotecan directly into the blood vessel of the eye will improve the treatment of retinoblastoma. This method is referred to as "selective intra-ophthalmic artery chemotherapy" (SIOAC).
The goals of this study are:
- To find out if topotecan is an effective treatment for retinoblastoma when delivered directly to the ophthalmic artery (SIOAC delivery)
- To find out what kind of effects (good and bad) can be expected when topotecan is given by SIOAC
- To assess visual pathway function before and after the study therapy
- To learn more about the pharmacology (how your body handles the drug) of topotecan when delivered directly to the ophthalmic artery
Studieoversigt
Status
Betingelser
Intervention / Behandling
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Tidlig fase 1
Kontakter og lokationer
Studiesteder
-
-
Ohio
-
Cincinnati, Ohio, Forenede Stater, 45229
- Cincinnati Children's Hospital Medical Center
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Age: 15 years of age or younger
- Diagnosis: Patients with untreated Group C/D/E unilateral Retinoblastoma at presentation without an indication for immediate enucleation (neovascular glaucoma or orbital pain) (Stratum A), or patients with a history of bilateral retinoblastoma and recurrent and/or refractory intraocular retinoblastoma where chemotherapy, external beam radiation and/or enucleation remain the only known option for disease control (Stratum B).
- Therapeutic Options: Chemotherapy, External Beam Radiation therapy and/or Enucleation
- Lansky ≥ 50 for patients ≤ 10 years of age; Karnofsky ≥ 50 for patients > 10 years of age. Patients who are unable to walk because of paralysis, but who are up in a wheelchair, will be considered ambulatory for the purpose of assessing the performance score.
- Prior Therapy: Stratum A: No prior therapy is allowed. Stratum B: Patients must have local relapsed/refractory disease after receiving standard upfront therapy involving at least one chemotherapeutic regimen. There is no limit to prior chemotherapeutic regimens permitted. Prior radiation therapy is permitted.
Patients must have recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to entering this study, as described below:
- Myelosuppressive chemotherapy: patients must not have received myelosuppressive chemotherapy within 3 weeks of study enrollment.
- Biologic therapies: Patients must not have received biologic anti-cancer agents within one week of study enrollment.
- Radiation therapy: Four weeks must have elapsed since external beam radiation therapy, if given.
Adequate Bone Marrow Function Defined as:
- Peripheral absolute neutrophil count (ANC) greater than or equal to 750/uL
- Platelet count greater than or equal to 75,000/uL (transfusion independent, defined as not receiving platelet transfusions within a 7-day period prior to enrollment)
- Hemoglobin greater than or equal to 8.0 gm/dL (may receive RBC transfusions)
Adequate Renal Function Defined as:
-Maximum serum creatinine based on age as follows: 1 to < 2 years- 0.6 mg/dL; 2 to < 6 years - 0.8 mg/dL; 6 to < 10 years- 1 mg/dL; 10 to < 13 years- 1.2 mg/dL; 13 to 15 years- 1.5 mg/dL for boys and 1.4 mg/dL for girls.
OR
Creatinine clearance or radioisotope GFR greater than or equal to 70ml/min/1.73 m2
Adequate Liver Function Defined As:
- Bilirubin (sum of conjugated + unconjugated) less than or equal to 1.5 x upper limit of normal (ULN) for age
- SGPT (ALT) less than or equal to 5 x upper limit of normal (ULN) for age
- Serum albumin greater than or equal to 2 g/dL
- Informed Consent: All patients and/or their parents or legal guardians must sign a written informed consent. Assent, when appropriate, will be obtained according to institutional guidelines.
- Patients of child-bearing potential must have a negative pregnancy test and agree to use an effective birth control method (abstinence is an acceptable form of birth control).
Exclusion Criteria:
- Extra-ocular retinoblastoma or retinoblastoma involving the anterior chamber
- Retinoblastoma that could otherwise be treated with laser therapy, cryotherapy, or plaque therapy only
- Structural brain abnormality
- Uncontrolled infection, defined as requiring intravenous antibiotics at the time of enrollment
Concomitant Medications
- Growth factors that support platelet or white cell number or function must not have been administered within 3 days prior to enrollment.
- Patients who are currently receiving non-FDA approved drugs, or who have received a non-FDA approved drug within 7 days prior to enrollment, are ineligible.
- Patients who are currently receiving other anti-cancer agents are ineligible.
- Patients who in the opinion of the investigator may not be able to comply with the safety monitoring requirements of the study are not eligible.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: N/A
- Interventionel model: Enkelt gruppeopgave
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
---|---|
Eksperimentel: Treatment of Retinoblastoma
Study of Intra-Ophthalmic Artery Topotecan infusion for the Treatment of Retinoblastoma.
|
Topotecan via intra-ophthalmic artery delivery infused over 30 minutes on Day 1 of every 21-day cycle.
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
1-year event-free survival (event defined as the need for external beam radiation or enucleation)
Tidsramme: 1 year
|
1 year
|
|
Response rate of retinoblastoma to topotecan when administered directly into the ophthalmic artery.
Tidsramme: Up to 18 weeks
|
EUA and retCAM imaging will be used to assess response rate.
|
Up to 18 weeks
|
Local (ocular) toxicities associated with the proposed regimen. Toxicities assessed using clinical examinations (EUA and Teller cards and Allan figures or Snellen visual acuity charts or other measures as appropriate for child's age.)
Tidsramme: Up to 12 months
|
|
Up to 12 months
|
Patterns of response of retinoblastoma to topotecan when administered directly into the ophthalmic artery.
Tidsramme: Up to 18 weeks
|
Physical examination of the tumors will be recorded at baseline and at every tumor assessment visit.
Tumors will be classified as having Type I, II, III, IV, V or O response based on characteristic features identified during physical examination.
|
Up to 18 weeks
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Visual pathway function
Tidsramme: Up to 12 months
|
Evaluation of visual pathway function will be measured using visual acuity, electroretinogram, visual evoked potential, and functional magnetic resonance imaging.
|
Up to 12 months
|
Pharmacokinetics (Cmax and AUC) of topotecan when administered directly into the ophthalmic artery.
Tidsramme: Samples taken 15 and 60 minutes after topotecan administration on Day 1 of Cycle 1 (optional for patients)
|
Samples taken 15 and 60 minutes after topotecan administration on Day 1 of Cycle 1 (optional for patients)
|
|
Histologic findings in the eyes ultimately requiring enucleation.
Tidsramme: At time of enucleation, only if indicated
|
Any eye requiring enucleation will be assessed for the presence or absence of 'high risk' features defined as scleral or massive choroidal invasion of viable tumor, anterior chamber involvement, invasion of the optic nerve posterior to the lamina cribrosa, ciliary body or iris invasion.
|
At time of enucleation, only if indicated
|
Samarbejdspartnere og efterforskere
Efterforskere
- Ledende efterforsker: James Geller, MD, Children's Hospital Medical Center, Cincinnati
Publikationer og nyttige links
Datoer for undersøgelser
Studer store datoer
Studiestart
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
- Neoplasmer efter histologisk type
- Neoplasmer
- Neoplasmer efter sted
- Neoplasmer, kirtel og epitel
- Øjensygdomme
- Nethindesygdomme
- Neoplasmer, Neuroepithelial
- Neuroektodermale tumorer
- Neoplasmer, kimceller og embryonale
- Neoplasmer, nervevæv
- Øjensygdomme, arvelig
- Øjeneoplasmer
- Retinale neoplasmer
- Retinoblastom
- Molekylære mekanismer for farmakologisk virkning
- Enzymhæmmere
- Antineoplastiske midler
- Topoisomerasehæmmere
- Topoisomerase I-hæmmere
- Topotecan
Andre undersøgelses-id-numre
- IARB1
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Intra-Ophthalmic Artery Topotecan Infusion
-
Genesis Athens ClinicNational and Kapodistrian University of AthensRekrutteringOvergangsalderen | Amenoré | Infertilitet, kvinde | Anovulatorisk infertilitetGrækenland
-
Emory UniversityTexas Heart InstituteAfsluttetMyokardieinfarkt | KoronararteriesygdomForenede Stater
-
Royan InstituteAfsluttetTilbagevendende implantationsfejlIran, Islamisk Republik
-
Medical College of WisconsinRekruttering
-
Ospedale San RaffaeleEuropean UnionAfsluttetType 1 diabetes | Postpancreatektomi HyperglykæmiItalien
-
Nicklaus Children's Hospital f/k/a Miami Children...AfsluttetTilbagevendende medulloblastom i barndommen | Tilbagevendende Childhood Ependymoma | Atypisk teratoid/rhabdoide tumor i barndommen | Embryonal tumor med rigelig neuropil og ægte rosetter | Metastatisk malign neoplasma til LeptomeningesForenede Stater
-
Genesis Athens ClinicNational and Kapodistrian University of AthensRekrutteringInfertilitet, kvinde | Perimenopausal lidelse | Unormal menstruationscyklusGrækenland
-
Ain Shams UniversityAfsluttet
-
National Cancer Institute (NCI)RekrutteringKolorektale neoplasmer | Kolorektal cancer | Cholangiocarcinom | Galdevejskræft | Galdekanalsneoplasmer | Metastatisk tyktarmskræft (Mcrc) | Intrahepatisk cholangiocarcinom (Icc) | Intrahepatisk galdevejskræftForenede Stater
-
St. Jude Children's Research HospitalCookies for Kids' Cancer; CURE Childhood Cancer, Inc.Aktiv, ikke rekrutterende